Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

doi:10.1158/1078-0432.ccr-1092-03

Article

Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2004

Botti Claudio, Buglioni Simonetta, Benevolo Maria, Giannarelli Diana, Papaldo Paola, Cognetti Francesco, Vici Patrizia, Di Filippo Franco, Del Nonno Franca, Venanzi Franco Maria, Natali Pier Giorgio, Mottolese Marcella

Abstract excerpt

PURPOSE: To determine the prognostic value of Fas receptor and Fas ligand (FasL) as apoptosis-related biomarkers in the context of chemoresponsiveness in breast cancer (BC) patients submitted to anthracycline-based adjuvant therapy. EXPERIMENTAL DESIGN: Fas and FasL were investigated by immunohis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Abstract excerpt

Topics

Related research